The EPO published patent application EP3930736A1 for recombinant bacteria technology developed by researchers Yongliang Zhang and Chin Wen PNG at the National University of Singapore. The patent application has been published with kind code A1, indicating it has passed formal examination and is now publicly available. IPC classifications indicate pharmaceutical applications including drug delivery systems (A61K 35/744), anticancer agents (A61P 35/00), anti-inflammatory agents (A61P 29/00), and protein/peptides (C07K 14/195, C07K 14/31) derived from bacterial sources.

The patent is designated for all EU member states plus several non-EU European countries. This publication gives the National University of Singapore intellectual property rights that could be enforced against third parties manufacturing or commercializing similar recombinant bacteria products in these jurisdictions. Biotech and pharmaceutical companies developing related bacterial-based therapeutics should review this patent for potential licensing needs or freedom-to-operate concerns.